12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arikace: Development ongoing

Insmed said FDA lifted the clinical hold on development of Arikace in CF patients with P. aeruginosa lung infection. Insmed said it reached an agreement with the agency on a revised patient population for a planned Phase III trial, which will enroll adult CF patients who have chronic Pseudomonas lung infections and a predicted forced expiratory volume in 1 second (FEV1) percentage between...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >